Atherosclerosis is complex vascular disorder involving the interplay between inflammation, coagulation and lipid metabolism. There is increasing evidence that platelet activation but may play important roles in the initiation and/or expansion of atherosclerotic lesions. As platelets contain diverse modulators of inflammation, cell adhesion and endothelial activation, elucidating the mechanisms by which platelets promote atherogenesis may offer novel opportunities for intervention. My group has focused on the involvement of the platelet specific chemokine platelet factor 4 (PF4) in atherosclerosis. We have generated preliminary data in vivo that support the notion that PF4 is proatherogenic. Previous work from our laboratory has defined two receptor dependent pathways that may be responsible for PF4 atherogenicity. First, PF4 inhibits low density lipoprotein receptor (LDLR) dependent low density lipoprotein (LDL) degradation. This results in retention of LDL on the cell surface, which is prone to modification into oxidized LDL (ox-LDL). Second, PF4 activated NF-kB (a transcription factor involved in atherosclerosis and inflammation) via the LDL receptor related protein (LRP). The overriding hypothesis of this proposal is that PF4 activates one or both of these pathways to promote atherosclerotic lesion formation. We further posit that PF4 tetramers oligomerize in the presence of cell surface glycosaminoglycans (GAGs) before activation of the LDLR and/or LRP pathways. To test this hypothesis, we will study the effect of PF4 on atherosclerosis in vivo and elucidate its mechanism of action both in vivo and on vascular cells using in vitro model systems through three related Specific Aims: SA I: """"""""Structural features of PF4 that contribute to proatherogenicity"""""""" will further dissect the details of these pathways in vitro, focusing on structural characteristics of PF4. SA II: """"""""Characterize the effects of PF4 on lipoprotein metabolism and atherosclerosis in apoE-/- mice"""""""" will expand our characterization of apoE-/- mice lacking PF4, as well as to understand the implications of PF4 overexpression in apoE-/- mice. SA III: """"""""Mechanism of PF4 proatherogenicity in vivo"""""""" will examine the importance of both the LDLR and LRP pathways for PF4 mediated atherogenesis. These studies will provide novel insights into the role of PF4, the most abundant protein released by activated platelets, on the development of atherosclerosis, delineate the pathways by which this occurs in vivo, and suggest potential methods to intervene in atherogenesis

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL078726-05
Application #
7775093
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Kindzelski, Andrei L
Project Start
2006-02-07
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2012-01-31
Support Year
5
Fiscal Year
2010
Total Cost
$384,759
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Cho, Michael Jeffrey; Lo, Agnes S Y; Mao, Xuming et al. (2014) Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nat Commun 5:4167
Litvinov, Rustem I; Yarovoi, Serge V; Rauova, Lubica et al. (2013) Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. J Biol Chem 288:33060-70
Cuker, Adam; Rux, Ann H; Hinds, Jillian L et al. (2013) Novel diagnostic assays for heparin-induced thrombocytopenia. Blood 121:3727-32
Sachais, Bruce S; Litvinov, Rustem I; Yarovoi, Serge V et al. (2012) Dynamic antibody-binding properties in the pathogenesis of HIT. Blood 120:1137-42
Sachais, Bruce S; Rux, Ann H; Cines, Douglas B et al. (2012) Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood 119:5955-62
Tanhehco, Yvette C; Rux, Ann H; Sachais, Bruce S (2011) Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis. Transfusion 51:1022-9
Sachais, Bruce S; Turrentine, Tiffany; Dawicki McKenna, Jennine M et al. (2007) Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice. Thromb Haemost 98:1108-13